Associated Papers
Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
38386293 (PubMed )
Supplement: ccr-23-0372_supplemental_table_2_suppst2.xlsx › Suppl._Table_2
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients.
Bonifacio M et al.
Annals of Hematology, 2019
A novel somatic CALR mutation in essential thrombocythemia and effective response to interferon-alfa-2b therapy.
Zhang X et al.
Blood Cells, Molecules & Diseases, 2018
Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.
Lim KH et al.
Oncotarget, 2017
Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
Murugesan G et al.
International Journal of Laboratory Hematology, 2016
Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia.
Rashid M et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion, 2016
Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2016
Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms.
Kondo T et al.
Springerplus, 2016
Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring.
Chi J et al.
Annals of Hematology, 2015
Calreticulin mutations and long-term survival in essential thrombocythemia.
Tefferi A et al.
Leukemia, 2014
Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis.
Chi J et al.
Leukemia, 2014
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
Nangalia J et al.
The New England Journal of Medicine, 2013
Select a paper to view details